These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Nuclease production and lysostaphin susceptibility of Staphylococcus aureus and other catalase-positive cocci. Lachica RV; Hoeprich PD; Genigeorgis C Appl Microbiol; 1971 May; 21(5):823-6. PubMed ID: 5574317 [TBL] [Abstract][Full Text] [Related]
26. [Comparative antibiotic sensitivity of different species of staphylococci isolated from humans]. Bogdanova LF; Afanas'eva TI; Vlasova IV; Solov'eva VE; Sobolev VR Antibiotiki; 1976 Nov; 21(11):985-8. PubMed ID: 1020935 [TBL] [Abstract][Full Text] [Related]
27. Rapid lysostaphin test to differentiate Staphylococcus and Micrococcus species. Geary C; Stevens M J Clin Microbiol; 1986 Jun; 23(6):1044-5. PubMed ID: 3519667 [TBL] [Abstract][Full Text] [Related]
28. [Studies with lysotaphin. II. Lysostaphin sensitivity of 230 strains of Staph. aureus of animal origin]. Pulverer G Z Med Mikrobiol Immunol; 1968; 154(1):49-53. PubMed ID: 5751715 [No Abstract] [Full Text] [Related]
29. Effect of BiTek agar on lysostaphin susceptibility of staphylococci. Langlois BE; Dawson K; Akers K J Clin Microbiol; 1990 Nov; 28(11):2568-9. PubMed ID: 2254432 [TBL] [Abstract][Full Text] [Related]
30. Reduced vancomycin susceptibility and increased macrophage survival in Staphylococcus aureus strains sequentially isolated from a bacteraemic patient during a short course of antibiotic therapy. Basco MDS; Kothari A; McKinzie PB; Revollo JR; Agnihothram S; Azevedo MP; Saccente M; Hart ME J Med Microbiol; 2019 Jun; 68(6):848-859. PubMed ID: 31136294 [TBL] [Abstract][Full Text] [Related]
32. In-vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative staphylococci. Raymond J; Vedel G; Bergeret M J Antimicrob Chemother; 1996 Dec; 38(6):1067-71. PubMed ID: 9023655 [TBL] [Abstract][Full Text] [Related]
33. Lysostaphin: an antistaphylococcal agent. Kumar JK Appl Microbiol Biotechnol; 2008 Sep; 80(4):555-61. PubMed ID: 18607587 [TBL] [Abstract][Full Text] [Related]
34. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. Becker SC; Foster-Frey J; Donovan DM FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148 [TBL] [Abstract][Full Text] [Related]
35. Rapid identification of Staphylococcus aureus by using lysostaphin sensitivity. Severance PJ; Kauffman CA; Sheagren JN J Clin Microbiol; 1980 Jun; 11(6):724-7. PubMed ID: 7430338 [TBL] [Abstract][Full Text] [Related]
36. [Current status of resistance of Staphylococcus in Spain. 4th National Study (1996). Work Group on the Study of Staphylococcus]. Cercenado E; Sánchez-Carrillo C; Alcalá L; Bouza E Rev Clin Esp; 1997 Sep; 197 Suppl 2():12-8. PubMed ID: 9441317 [No Abstract] [Full Text] [Related]
37. Relationship between lysostaphin endopeptidase production and cell wall composition in Staphylococcus staphylolyticus. Robinson JM; Hardman JK; Sloan GL J Bacteriol; 1979 Mar; 137(3):1158-64. PubMed ID: 438117 [TBL] [Abstract][Full Text] [Related]
38. Purification and characterization of the antibacterial peptidase lysostaphin from Staphylococcus simulans: Adverse influence of Zn Chandra Ojha S; Imtong C; Meetum K; Sakdee S; Katzenmeier G; Angsuthanasombat C Protein Expr Purif; 2018 Nov; 151():106-112. PubMed ID: 29944958 [TBL] [Abstract][Full Text] [Related]
39. Growth inhibition of unusual strains of Staphylococcus aureus by lysostaphin and other antistaphylococcal antibiotics. Zygmunt WA; Browder HP; Tavormina PA Can J Microbiol; 1966 Apr; 12(2):341-5. PubMed ID: 5929159 [No Abstract] [Full Text] [Related]
40. Susceptibility of Staphylococcus epidermidis to lysostaphin and major antimicrobial agents. Pulverer G; Jeliaszewicz J Chemotherapy; 1973; 19(2):109-14. PubMed ID: 4762803 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]